Synthesis and Evaluation of a New Series of Thiazolyl-pyrazoline Derivatives as Cholinesterase Inhibitors
Journal Title: Turkish Journal of Pharmaceutical Sciences - Year 2018, Vol 15, Issue 3
Abstract
Objectives: In recent years, the design of anticholinesterase agents based on molecular hybridization of pharmacologically active scaffolds has attracted a great deal of interest in medicinal chemistry. For this purpose, we aimed to design and synthesize anticholinesterase agents based on the molecular hybridization of thiazole and pyrazoline scaffolds. Materials and Methods: New thiazolyl-pyrazoline derivatives were synthesized via the ring closure reaction of 3-(2-furyl)-5-(1,3-benzodioxol-5-yl)-1-thiocarbamoyl-4,5-dihydro-1H-pyrazole with 2-bromo-1-arylethanone derivatives. The compounds were investigated for their inhibitory effects on AChE and BuChE using a modification of Ellman’s spectrophotometric method. As a part of this study, the compliance of the compounds to Lipinski’s rule of five was evaluated. The physicochemical parameters (log P, TPSA, nrotb, molecular weight, number of hydrogen bond donors and acceptors, molecular volume) were calculated using Molinspiration software. Results: 2-[5-(1,3-Benzodioxol-5-yl)-3-(2-furyl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(naphthalen-2-yl)thiazole was found to be the most effective AChE inhibitor (38.5±2.85%), whereas 2-[5-(1,3-benzodioxol-5-yl)-3-(2-furyl)-4,5-dihydro-1H-pyrazol-1-yl]-4-(4-fluorophenyl)thiazole was found as the most potent BuChE inhibitor (43.02±2.71%) in this series. These compounds only violated one parameter of Lipinski’s rule of five. On the basis of Lipinski’s rule, they were expected to have reasonable oral bioavailability. Conclusion: In the view of this study, the structural modification of the identified compounds is on-going for the generation of new cholinesterase inhibitors with enhanced efficacy.
Authors and Affiliations
Halide Edip TEMEL, Mehlika Dilek ALTINTOP, Ahmet ÖZDEMİR
Keywords
Related Articles
- EP ID EP421244
- DOI 10.4274/tjps.20982
- Views 131
- Downloads 0
Desloratadine-Eudragit® RS100 Nanoparticles: Formulation and Characterization
Objectives: The objective of the present study was to formulate Desloratadine-Eudragit® RS100 nanoparticles and investigate the characteristics of the prepared nanoparticles. Materials and Methods: The nanoparticles wer...
Polymorphisms and Protein Expressions of Glutathione S-Transferase M1 and T1 in Non-Small Cell Lung Cancer
Objectives: The deletion polymorphisms of glutathione S-transferase (GST) GSTM1 and GSTT1 genes result in the absence of the corresponding protein, which decreases the detoxification of carcinogens. Studies evaluating po...
A Review on: Phase ‘0’ Clinical Trials or Exploratory Investigational New Drug
In a move to speed up the development of new medicines, the Food and Drug Administration announced in January 2006 the creation of the exploratory Investigational New Drug (IND), the so-called phase ‘0’ clinical trials....
Development and Full Validation of a Stability-indicating HPLC Method for the Determination of the Anticancer Drug Temozolomide in Pharmaceutical Form
Objectives: In the present study, an accurate, precise and simple method has been developed for the determination of TMZ in its pharmaceutical form by using HPLC. Materials and Methods: An HPLC method with a DAD was vali...
Enhancement of Dissolution of Fenofibrate Using Complexation with Hydroxy Propyl β-Cyclodextrin
Objectives: The aim of the present study was to enhance the dissolution rate of fenofibrate using complexation with hydroxy propyl β-cyclodextrin (HPβCD). Materials and Methods: The phase solubility behavior of fenofibra...